Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain by Pegah Varamini & Istvan Toth
REVIEW ARTICLE
published: 13 December 2013
doi: 10.3389/fphar.2013.00155
Lipid- and sugar-modified endomorphins: novel targets for
the treatment of neuropathic pain
Pegah Varamini1 and Istvan Toth1,2*
1 Medicinal Chemistry Department, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
2 Medicinal Chemistry Department, School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
Edited by:
Susan Hua, The University of
Newcastle, Australia
Reviewed by:
Karen K. Szumlinski, University of
California, Santa Barbara, USA
George Kokotos, University of
Athens, Greece
Robin Polt, The University of
Arizona, USA
*Correspondence:
Istvan Toth, School of Chemistry and
Molecular Biosciences, The
University of Queensland,
Chemistry Bld. 68, Cooper Road, St.
Lucia, Brisbane, QLD 4072, Australia
e-mail: i.toth@uq.edu.au
Endomorphins are endogenous opioid peptides that cause potent antinociception in
rodent models of acute and neuropathic pain with less undesirable side effects
than opioid alkaloids. However, endomorphins are poorly suited to clinical applications
because of low membrane permeability and a susceptibility to enzymatic degradation.
Glycosylation and lipidation have proven to be two of the most robust approaches
for the generation of new therapeutic endomorphin derivatives. Conjugation with
lipoamino acids (LAA) confers an amphipathic character to the peptide, which improved
interaction between the peptide and the lipid bilayer of the cell membranes, increasing
permeability. Glycosylation can also improve peptide stability and blood brain barrier
(BBB) transport. It is believed that an endocytotic mechanism (transcytosis) is responsible
for the systemic delivery of water-soluble glycopeptides. This review discusses the
application of glycosylation and lipidation strategies to improve the drug-like properties of
endomorphins. Pharmacologically active endomorphin analogs with less adverse effects
are also discussed.
Keywords: endomorphin, peptide delivery, neuropathic pain, lipoamino acid, glycosylation, lipopeptide,
glycopeptide, blood brain barrier
INTRODUCTION
Opioid analgesics such as morphine are among the most com-
monly used for the treatment of severe pain. Although opioid
analgesics are useful for the relief of nociceptive pain, their
efficacy against neuropathic pain is limited. Furthermore, they
are associated with a range of undesirable side effects such
as constipation, respiratory depression, tolerance, and physical
dependence, particularly with long-term use. Investigations into
new effective treatments for neuropathic pain that could replace
opioid alkaloids have predominantly focused on the develop-
ment of peptide analogs with selectivity for μ-opioid (MOP)
receptors (Vaccarino and Kastin, 2000). In order to be effec-
tive as an analgesic for clinical application, the peptide analog
must confer high bioavailability, which is achieved through good
blood brain barrier (BBB) permeability and resistance to enzy-
matic degradation. Delivery of pharmaceutical agents to the
brain is highly challenging (Banks et al., 1992). Various proper-
ties combine to make the BBB a formidable barrier, including
tight junctions, minimized surface area, electrostatic interac-
tions and increased metabolism, as well as an active efflux sys-
tem. Different approaches have been used to improve the brain
penetration of pharmaceutical agents (Banks and Kastin, 1985;
Begley, 1996). Endomorphin-1 and -2 are naturally occurring
peptides with excellent therapeutic potential as replacements for
morphine-like opioids. They are potent, highly selective MOP
receptor agonists with remarkable anti-neuropathic properties
in different rodent models of neuropathic pain (Przewlocki and
Przewlocka, 2001) and cause less adverse effects than opioid
alkaloids (Vaccarino et al., 1999; Czapla et al., 2000). Nevertheless,
like most peptide neurotransmitters and neuromodulators in the
CNS, modifications are required to transport endomorphins to
the brain.
HISTORICAL PERSPECTIVE
All endogenous opioid peptides that contain Tyr-Gly-Gly-Phe
(including endorphins, enkephakins, and dynorphins), possess
affinity for the three opioid receptors: μ (MOP), δ (DOP),
and κ (KOP), with low to moderate specificity. β-endorphins
have comparable affinity for both MOP and DOP receptors. Met-
and leu-enkephalins are DOP receptor endogenous ligands and
dynorphins are ligands of KOP receptors. Mammalian peptides
with high selectivity and affinity for MOP receptors were not
known until the discovery of endomorphins. In 1997, Zadina
et al.. replaced the Gly in the endogenous peptide sequence
(Tyr-Pro-Trp-Gly-NH2) which had high MOP receptor selec-
tivity, but low affinity (Hughes et al., 1975),with all possible
natural amino acids (Zadina et al., 1997). Among all deriva-
tives, the Phe-substituted sequence showed the highest affinity
and selectivity for MOP receptors and was called endomorphin-
1 (Tyr-Pro-Trp-Phe-NH2). Endomorphin-1 and -2, (Tyr-Pro-
Phe-Phe-NH2) (Figure 1) were first isolated from bovine brain
(Zadina et al., 1997) and then from human cortex (Hackler
et al., 1997). Although the precursor(s) of endomorphins remain
unidentified, their extraordinarily high affinity and selectivity for
MOP receptors in the brain supports the proposal that they are
endogenous MOP receptor ligands.
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STRATEGIES TO IMPROVE BIOAVAILABILITY
Different strategies have been investigated for the effective
delivery of endomorphin.
Use of peptidase inhibitors such as tripeptides diprotin A and
B, Tyr-Pro-Ala-NH2 (EMDB-2), and Tyr-Pro-Ala-OH (EMDB-
3), enhanced and prolonged the antinociceptive effects of endo-
morphins (Sakurada et al., 2003; Cravezic et al., 2011). However,
due to the need for central administration of both peptides and
peptidase inhibitors (Fichna et al., 2010; Cravezic et al., 2011),
this approach achieved a low degree of success.
Several strategies have been developed tomanipulate the struc-
ture of endomorphins. The current data indicate that is confor-
mational adaptation of the neuropeptides to the different MOP,
DOP, and KOP receptor topographies. Thus, the design of con-
formationally restricted analogs is of great importance for the
selective targeting of a single distinct receptor type (Schiller and
DiMaio, 1982). The greater rigidity of the bioactive peptide epi-
tope affects the receptor binding affinity in a receptor-specific way
(Bock et al., 2013). Therefore, selectivity of the peptide can be
tuned based on the level of conformational restriction imposed
by the constraints (Clark et al., 2010).
Glycosylation and lipidation are two successful strategies
where peptide conformation is locally restricted. The incorpora-
tion of lipids and sugars as conformational constraints (Hruby
et al., 1990; Kawai et al., 1990; Hruby and Balse, 2000) sig-
nificantly improved the pharmacological properties of various
peptides (Polt et al., 1994; Egleton et al., 2000; Falconer and Toth,
2007; Cros et al., 2011).
GLYCOSYLATION
Conjugation of carbohydrates to peptides increased the biodis-
tribution of opioid peptides by enhancing permeation across
intestinal epithelium and BBB via natural transporters (Poduslo
and Curran, 1994; Egleton and Davis, 2005). Membrane pro-
teins such as glucose transporters, GLUT and SGLUT, allowed
for the uptake of specific carbohydrates through active, or facil-
itated transport pathways to deliver peptides across biological
barriers (Wood and Trayhurn, 2003). In spite of difficulties asso-
ciated with their synthesis (Buskas et al., 2006), carbohydrates
improved the water solubility, stability and bioavailability of the
peptide analogs (Albert et al., 1993; Polt et al., 1994; Negri et al.,
1999; Bilsky et al., 2000; Egleton et al., 2000). Although glycosy-
lation reduces passive diffusion of the peptides by reducing their
FIGURE 1 | The structure of endomorphin-1 and -2.
lipophilicity, it makes the peptide a favorable substrate for glucose
transporters. Thus, this modification often results in increased
penetration through the BBB and GI membranes (Horvat, 2001;
Gentilucci, 2004). However, the exact mechanism through which
glycosylation improves BBB or GI transport is yet to be eluci-
dated. Octanol/saline distribution studies indicated that transport
does not occur via passive diffusion, due to significantly lower
lipophilicity (Egleton et al., 2000). Alternatively, the amphipathic
nature of glycopeptides was suggested to be responsible for their
enhanced permeability through barriers particularly BBB (Palian
et al., 2003). For the glycopeptides to be effectively delivered to
the brain, it is necessary to produce “biousian” activity (Polt
et al., 2005a). Ousia means “essence” in Greek. It is important
for the glycopeptides to have two essences, an amphipathic state
that promotes adsorption to biological membranes and a ran-
dom coil state that is water-soluble. Biousian effect enabled the
compound to undergo endocytosis or permits “membrane hop-
ping” (Egleton et al., 2005). Through extensive studies on a library
of glycopeptides, negative membrane curvature on the surface
of endothelial cells was shown to be promoted by permeable
glycopeptides (Dhanasekaran et al., 2005). This in turn led to
an increase in BBB transport (Figure 2) (Broadwell et al., 1988;
Egleton et al., 2001; Polt et al., 2005b).
Distribution and pharmacodynamic of the peptides are
immensely affected by glycosylation. This allows glyco-
sidic moieties to be used as vectors for targeting specific
carbohydrate-recognition receptors (Eduardo, 1994).
LIPIDATION
Lipidation is a post-translational peptide modification that sig-
nificantly influences the properties of peptides and is used in the
design of peptide drugs. The presence of polar groups reduced
the peptides’ partition coefficients and subsequently decreased
their membrane permeability (Chikhale et al., 1994). Lipidation
provided a simple way to modulate peptide lipophilicity, and
facilitates their interaction with cell membranes and penetration
across biological barriers by passive diffusion (Balaz, 2000; Griffin
and O’Driscoll, 2011). Through increasing the membrane-like
properties of the peptides, lipidation improved their interac-
tion with the lipid bilayer within the cell membrane (Pignatello
et al., 2005). Both lipoamino acids (LAA) and fatty acid chains
have been attached to the peptides to enhance their permeability
across biological membranes (Desino et al., 2009). LAAs are α-
amino acids with varying length (usually C8–20) alkyl side chains
(Figure 3). Having both the hydrophobic properties of lipids and
the hydrophilic characteristics of α-amino acids, LAAs are appro-
priate conjugates to incorporate into the structure of peptides
(Toth, 1994; Kokotos et al., 1996). Although the conjugation of
fatty acids to the peptides will ultimately result in an increase
FIGURE 2 | Endocytosis of glucopeptides (Polt, 2008).
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FIGURE 3 | Structure of lipoamino acids.
in their lipophilicity, the addition of LAAs is more advantageous
due to their amphipathic character (Toth, 1994). In addition it
plays an important role in enhancing peptide’s stability against
enzymatic degradation (Wang et al., 2006). This in turn affects
the absorption, distribution, metabolism and excretion (ADME)
and bioavailability of drugs and makes it an attractive strategy to
convert peptides into drug leads (Silvius, 2002).
PHYSIOLOGICAL AND PHARMACOLOGICAL PROPERTIES OF
LIPO- AND GLYCO-ENDOMORPHINS
METABOLIC STABILITY AND MEMBRANE PERMEABILITY
Lipoamino acid modification
The endogenous opioid peptide leu-enkephalin was chemically
modified by a lipophilic dimethylmaleic anhydride analog. This
analog showed a 12- and 32-fold increase in mouse small intesti-
nal mucosal homogenate and liver homogenate (Wang et al.,
2006).
A series of glycosylated endomorphin-1 peptides were synthe-
sized by modifying either the N- or C-terminus of endomorphin-
1 with glucose succinate or glucose, respectively. The half-life of
the analog conjugated with glucose at the N-terminus increased
from 5min for endomorphin-1 to 38min in the Caco-2 cell
homogenates. However, the C8LAA-modified glycosylated ana-
log produced even higher stability in the Caco-2 cell homogenate
assay with a half-life of 75min (Koda et al., 2008). Although
there was a 3-fold increase in the apparent permeability (Papp)
of glucose-C8LAA derivative, this was not as pronounced as
the Papp of the compounds modified only with C8LAA com-
pared to endomorphin-1. Due to a significant reduction in the
receptor binding affinity of the C8LAA analog, a further mod-
ification was performed on the backbone structure of the par-
ent peptide. The unnatural amino acid 2′,6′-dimethyltyrosine
(Dmt) the more hydrophobic and conformationally restricted
residue compared to Tyr (Figure 4). Substitution of Tyr with
Dmt was shown to enhance the MOP receptor binding affinity
and potency of several opioid peptides (Li et al., 2005) including
endomorphin-1 (Jinsmaa et al., 2006). Therefore, a Dmt analog,
C8LAA[Dmt1]endomorphin-1 was synthesized which preserved
MOP receptor binding affinity (0.08 nM) relative to the parent
peptide. This analog exhibited enhanced stability and perme-
ability (Koda et al., 2008). In another trial, the 10-carbon LAA
FIGURE 4 | Structure of Tyrosine and 2′,6′-dimethyltyrosine.
modified peptides with/without substitution of Tyr1 with Dmt1
were examined for their biological activity. These endomorphin-
1 analogs produced 2–3.5 times higher stability and 2–2.6 times
higher permeability for Tyr1 and DMT1 analogs, respectively, in
comparison with their corresponding C8 derivatives (Varamini
et al., 2012b).
Substance P is a neuropeptide, which was first reported
to elicit analgesic activity in 1976 by Stewart et al. (Stewart
et al., 1976). Previously, a hybrid alkaloid/peptide compound,
comprised of morphine sulpfate bound to SP3−11, produced
a strong antinociceptive response with little or no develop-
ment of opioid tolerance or dependence (Kream, 2003; Kream
et al., 2007). C10LAA hybrid endomorphin-1 peptides were
designed and synthesized by conjugation of the last 4 or 5 C-
terminal amino acids of substance P (SP8−11 and SP7−11) with
all compounds bearing an overlapping Phe in the sequence. It
was proposed that the addition of substance P fragments to
lipo-endomorphin-1 may decrease the development of toler-
ance and physical dependence. Two C10-modified endomorphin-
1/SP hybrid peptides showed significantly improved half-life and
membrane permeability. However, of the two promising LAA-
modified derivatives with high stability and permeability, only
the one that contained the SP7−11 fragment produced potent
activity at MOP receptors with significant binding affinity and
retained selectivity. The docking scores obtained from confor-
mational studies were also in agreement with the Kiμ values
obtained in the receptor binding affinity experiments (Figure 5)
(Varamini et al., 2012a).
Glycosylation
A sugar-modified derivative of endomorphin was synthesized by
attachment of lactose succinamic acid to the peptide (Figure 6).
This glycosylated analog produced an unprecedented 700-fold
increase in membrane permeability and 21-fold increase in
plasma stability relative to the native peptide (Varamini et al.,
2012c). In this study a receptor-mediated or lactose selective
transporter-mediated absorption was suggested for as the mecha-
nism of transport across Caco-2 cell monolayer. According to the
Biopharmaceutics Classification System, there is a high correla-
tion between Caco-2 cell permeability coefficients (Papp values)
and fractional absorption values (Fa) in humans. This makes
the results from Caco-2 cell studies a reliable predictor of the
oral absorption of compounds in human (Smetanova et al.,
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FIGURE 5 | In vitro biological analyses revealed that the
C10LAA-modified analog conjugated with SP7−11 fragment was the
most promising derivative. (A) Structure of the compounds. (B) Surface
view of the active site of the MOP receptor for the highest docking score
conformation of MOP receptor with the compound docked into the active
site. For clarity, color of the atoms are as follows: blue—nitrogen,
red—oxygen, white—carbon (mu-opioid receptor), and green—carbon (on
ligand) (Varamini et al., 2012a).
FIGURE 6 | Structure of lactose succinamic acid-conjugated
endomorphin-1.
2011). Based on this classification, lactose-endomorphin-1 was
considered an ideal candidate for oral delivery.
Opioid peptides are predominantly cleared from the body via
fecal-oral routes (Weber et al., 1992; Witt et al., 2001). It has pre-
viously been shown that shifting from hepatic to renal clearance
can increase plasma stability and improve the antinociceptive
effects of opioid peptides (Witt et al., 2001). Since hydrophilic-
ity of the glycopeptides is increased compared with the parent
peptides, it is plausible that glycosylation shifts elimination to the
renal pathway, thus contributing to the higher stability of these
conjugates.
In vivo ANTINOCICEPTIVE ACTIVITY
Lipoamino acid modification
Targeting of neuropeptide drugs to the CNS through systemic
and oral delivery routes is a formidable obstacle. The delivery of
peptide drugs is limited by their poor bioavailability to the brain
due to low metabolic stability, high clearance by the liver, and the
obstacle posed by the BBB (Egleton et al., 2001).
The 8- and 10-carbon LAA derivatives of endomorphin-1,
with either Tyr or Dmt at position 1, have been shown to produce
significant dose dependent analgesia in a chronic constriction
injury (CCI) model of pain in rats. This analgesia was opi-
oid receptor-mediated and was produced following intravenous
(i.v.) administration. The two C10LAA-modified endomorphin-
1 peptides produced higher potency than C8LAA analogs and
even morphine in this model of rats with ED50 values of
about 1μmol/kg. However, no significant difference was observed
between ED50 values obtained for lipo-endomorphin-1 analogs
with Tyr1 as in the native form of the peptide, or Dmt1 in the
modified form. Although C8-Endo-1 and C8-Dmt-Endo-1 (Koda
et al., 2008) were reported to have higher MOP receptor bind-
ing affinity and agonist activity than their corresponding C10-
peptides, their potency in relieving neuropathic pain in CCI rats
was less than C10-analogs. The higher antinociceptive potency
of C10-modified peptides compared to C8-modified analogs was
explained by the increase in their permeability and metabolic
stability. Longer alkyl chain length possibly increased analgesic
activity by permitting improved transport across lipophilic mem-
branes including the BBB (Varamini et al., 2012b). Furthermore,
these lipidated analogs did not cause significant respiratory
depression (Varamini et al., 2013), or constipation, and resulted
in less tolerance thanmorphine at analgesic doses (Varamini et al.,
2012b). The effect of attaching LAA residues containing differ-
ent length of alkyl side chain to drug molecules with in vitro
monoamine oxidase inhibitory activity was also investigated.
Consistently, analogs with different LAAs produced significantly
different potencies (Pignatello et al., 2005). It is plausible that
the divergence in the antinociceptive and side effect profiles of
morphine and the lipidic endomorphin-1 derivatives may be
due to their different interactions with pharmacologically defined
MOP receptor subtypes (Dworkin et al., 2007). Opioid receptor
hetero-oligomerization was suggested to be responsible for the
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diverse pharmacology displayed by these compounds (Jordan and
Devi, 1999; Levac et al., 2002).
Glycosylation
To date, many glycosylated analogs of various neuropeptides such
as deltorphin (Negri et al., 1999), Met-enkephalin (Polt et al.,
1994; Egleton et al., 2000), and Leu-enkephalin (Bilsky et al.,
2000) have shown improved analgesic activity after peripheral
administration. Structure-activity studies of enkephalin-based
opioid glycopeptides revealed that disaccharide derivatives were
significantly more potent than any of the monosaccharides after
peripheral administration (Elmagbari et al., 2004). However,
there are only limited reports of the characterization of endo-
morphin glycopeptides because only few potent derivatives have
been developed so far. Biondi et al. synthesized glycosylated
endomorphin-2 analogs by conjugating glucose or 2,3,4,6-tetra-
O-acetyl glucose with the hydroxyproline (Hyp) residue. The
MOP receptor binding affinity and agonist activity was abolished
in all of these analogs therefore the compounds were not further
investigated for their in vivo pain relieving activity (Biondi et al.,
2006).
N-terminal conjugation of endomorphin-1 with lactose succi-
namic acid resulted in a significant antinociception following oral
administration to CCI rats. This effect was comparable with that
of morphine, for which various oral dosage forms are currently
in clinical use (Varamini et al., 2012c). In contrast to morphine,
the pain-relieving effect of the lactose-endomorphin-1 analog was
selective to the injured hindpaw with insignificant effects pro-
duced in the contralateral hindpaw. This effect was antagonized
by naloxone, which indicated the key role of opioid receptors
(Varamini et al., 2012c).
CONCLUSION
Endomorphins have been shown to elicit a potent pain relieving
effect in different acute and neuropathic pain models in ani-
mals after central administration. More importantly this effect
is concomitant with little to no undesirable side effects asso-
ciated with the application of opioids like morphine. These
promising effects have been strong motivation for investigators
to design and synthesize a substantial number of endomor-
phin derivatives. Numerous studies report developments in our
understanding of the structure activity relationship properties,
bioactive conformation, physiological characterizations, in vivo
and in vitro biological activity of endomorphin analogs. Over
fifteen years since the discovery of endomorphins, investiga-
tions have led to the production of derivatives with acceptable
selectivity andMOP receptor-binding affinity. However, only lim-
ited progress has been made in the production of compounds
with outstanding metabolic stability and membrane permeabil-
ity, while retaining their pharmacodynamic properties. These are
critical criteria in the field of peptide drug delivery to over-
come the obstacles and succeed in the development of periph-
erally active and BBB-permeable analgesics suitable for clini-
cal applications. Thus far, two of the most successful strategies
have been shown to be glycosylation and lipid modification.
Two examples are the development of an orally active lactose-
modified and systemically effective LAA-conjugated derivative
of endomorphin-1 with high potential for the treatment of
neuropathic pain.
This review highlights the two modifications that have made
the most improvements to the therapeutic and side effect profile
of endomorphins. Presently potent and promising lead com-
pounds have been developed which are prospective to proceed
from research to the pharmaceutical industry. These achieve-
ments are the outcome of extensive research having been made
to develop opioid peptide-based analgesics like endomorphins for
the effective management of neuropathic pain.
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